Enzymedica, Inc., the top manufacturer of enzyme supplements announces the appointment of Scott Sensenbrenner as Chief Executive Officer.
Sensenbrenner leadership brings a great mix of inspiration, operational experience and a passion for customer care. While his background includes working for Enzymatic Therapy where he built the market for several leading products such as GS500, IP-6, Esberitox, St. John’s Wort, and Remifemin. Along with Perrigo as Group Director of their Nutrition Division, OTC/nutritional organizations in the world with over $2 Billion in sales.
Most recently, Sensenbrenner served as Vice President of Marketing & Sales for Thorne Research a leading manufacturer and marketer of therapeutic supplements sold exclusively to health care practitioners.
As Chief Executive Officer, Sensenbrenner’
Tom Bohager, Enzymedica’s Founder and Operating Chairman will remain active in key decisions, sharing jointly with Sensenbrenner in the development of short and long range strategies for the company.
To learn more about Enzymedica, visit the company website. http://www.enzymedica.com
